Pycnogenol

Phase 3Small molecule

UUniversity of Zurich

Pycnogenol is one of 79 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

COVID-19Active, not recruiting

Coronary Artery DiseasePreclinical

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Pycnogenol

UUniversity of Zurich

Phase 3

1 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Calciferol

Activella

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 9

Benadryl

PParkedale

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphedema1 trial

Pycnogenol for the Treatment of Lymphedema

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00214032·2 enrolled

Trial1 trial

The Prevstain Trial

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 2·NCT04203043·338 enrolled

Coronary Artery Disease1 trial

Pycnogenol and Endothelial Function in Coronary Artery Disease

Completed·UUniversity of Zurich·N/A·NCT00641758·25 enrolled

COVID-191 trial

Pycnogenol® in Post-COVID-19 Condition

Active, not recruiting·UUniversity of Zurich·Phase 3·NCT05890534·153 enrolled

Breast Cancer1 trial

Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00064857·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Pycnogenol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pycnogenol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pycnogenol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Zurich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Zurich

Pycnogenol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphedema1 trial

Trial1 trial

Coronary Artery Disease1 trial

COVID-191 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News